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serum. The relevance of the rise in total RCOs for AGE forma-Advanced glycation and lipidoxidation of the peritoneal mem-
tion is demonstrated by a parallel increase in the generationbrane: Respective roles of serum and peritoneal fluid reactive
of pentosidine during incubations of PD effluents. In contrastcarbonyl compounds.
with RCOs present in glucose-rich PD fluid, RCOs diffusingBackground. Advanced glycation of proteins has been in-
from uremic circulation originate from both carbohydrates andcriminated in the progressive alteration of the peritoneal
membrane during chronic peritoneal dialysis (PD). Advanced lipids. Their role in the modification of peritoneal proteins is
glycation end products (AGEs) result from a modification of demonstrated by the immunohistochemical study of peritoneal
proteins by reactive carbonyl compounds (RCOs). RCOs re- tissue. Two AGEs and two ALEs increase in parallel in the
sulting from glucose breakdown are present in commercial PD mesothelial layers and in vascular wall of small arteries in the
fluid. They also accumulate in uremic plasma. The present peritoneum.
study was undertaken to evaluate the respective contribution Conclusions. Protein modification of the peritoneum is de-
of these two sources of RCOs in the genesis of peritoneal termined not only by RCOs originating in PD fluid, but also
AGEs. by RCOs originating from the uremic circulation. The present
Methods. Three major RCOs formed during heat steriliza- data might be relevant to current attempts to improve PD fluid
tion of PD fluid, that is, glyoxal, methylglyoxal, and 3-deoxyglu- toxicity by lowering its glucose content.
cosone, and total RCOs were measured in commercial PD fluid
and in PD effluent. The generation of pentosidine, used as a
surrogate marker for AGEs, during one-week incubations of
Sustained quality of the peritoneal membrane has be-PD fluid and effluent samples fortified with bovine serum albu-
min (BSA) was measured by high-performance liquid chroma- come a major determinant of the technical survival of
tography. Peritoneal samples were stained with antibodies spe- peritoneal dialysis (PD) [1]. The demonstration in pa-
cific for two AGEs derived from carbohydrate-dependent
tients on chronic PD that the peritoneal membrane un-RCOs, N e -(carboxymethyl)lysine (CML) and pentosidine, or
dergoes progressive advanced glycation has raised thefor two advanced lipoxidation end products (ALEs) derived
from lipid-dependent RCOs, malondialdehyde (MDA)-lysine possibility that advanced glycation end product (AGE)
and 4-hydroxynonenal (HNE)-protein adduct. formation contributes to morphological and functional
Results. Glyoxal, methylglyoxal, and 3-deoxyglucosone were alterations of the peritoneum [2–4]. The role of the highidentified in commercial PD fluid. Their levels in PD effluents
glucose content of PD fluids in fostering advanced glyca-decreased with dwell time probably by diffusion into blood
tion has thus been considered [5]. Major efforts havecirculation. In contrast, the levels of total RCOs were initially
low in commercial PD fluid, increased in PD effluent with dwell been undertaken over the last few years to improve nutri-
time probably by diffusion from circulation into the peritoneal tion and to sustain ultrafiltration by replacing glucose
cavity, and after 12 hours, reached values observed in uremic
with glucose polymers or amino acids [6–8]. An attendant
benefit of these newer solutions might be a reduced for-
mation of peritoneal AGEs.Key words: uremia, carbonyl stress, advanced glycation, lipoxidation,
non-enzymatic biochemistry. Heat sterilization of PD fluids degrades glucose into
products including reactive carbonyl compounds (RCOs),
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we have recently shown that RCOs derived not only 360 nm. The buffer gradient used for elution was 15 to
100% buffer B for 50 minutes; buffer A consisted offrom carbohydrates but also from lipids accumulate in
uremic plasma and contribute to the production of AGEs 0.08% trifluoroacetic acid and buffer B was 80% acetoni-
trile containing 0.1% trifluoroacetic acid.as well as of the advanced lipoxidation end products
(ALEs) in the body [14–16]. Recovery of GO, MGO, and 3-DG was evaluated in
distilled water and commercial PD fluids containing 1.36,The present study was undertaken to assess the respec-
tive roles of serum and PD fluid RCOs in the production 2.27, or 3.86% glucose (N 5 4 for each experiment).
Recovery ranged from 111.8 to 115.8% for 10 mmol/Lof AGEs in the peritoneum. We demonstrate that not
only PD fluid, but also serum-derived RCOs are impor- GO and from 111.7 to 119.2% for 20 mmol/L GO. For
MGO, recovery ranged from 97.5 to 107.2% for 5 mmol/Ltant in the genesis of AGEs. Furthermore, we report
that human peritoneal tissue proteins are modified not and from 106.5 to 110.4% for 10 mmol/L. For 3-DG,
recovery ranged from 99.3 to 124.2% for 25 mmol/L andonly by AGE but also by ALE formation. The concomi-
tant presence of both types of RCO-protein products from 100.9 to 119.0% for 50 mmol/L. Increasing glucose
concentration did not modify recovery. Coefficient ofimplies the diffusion of serum RCO precursors of both
carbohydrate and lipid origin. variation measured in the various PD solutions ranged
from 4.8 to 9.0% for GO, from 5.0 to 14.0% for MGO,
and from 1.1 to 17.2% for 3-DG.
METHODS
Peritoneal dialysis effluent and blood samples In vitro incubation experiments
Cell-free PD effluents and plasma samples were ultra-Seventeen nondiabetic PD patients (age range, 32 to
74 years old; PD duration range, 8 to 122 months) were filtrated twice through a filter with a 5000 D cut-off
value (Ultrafree CL-LCC; Nihon Millipore Ltd., Tokyo,investigated. PD was performed by four exchanges daily
(3 in the daytime and 1 overnight) with 3 L of PD fluids Japan) and were fortified with essentially fatty acid-free
grade bovine serum albumin (BSA; Sigma, St. Louis,containing 1.36% glucose (Dianeale; Baxter Health-
care, Round Lake, IL, USA). All patients gave an in- MO, USA) to the final concentration of 30 mg/mL. The
BSA had been dissolved in 0.1 mol/L phosphate bufferformed consent to participate in the study. Fresh hepa-
rinized plasma samples and PD effluents after a 12-hour (pH 7.2). The pH did not change during incubation,
with its value ranging from 7.0 to 7.5. The samples weredwell were obtained. In three PD patients, PD effluents
were collected, with informed consent, at 60, 120, 180, sterilized with a 0.22 mm pore filter and incubated under
air in sealed sterile 1.5 mL plastic tubes at 378C for one240, and 300 minutes and 12 hours during a standardized
12-hour dwell. The cells were separated by centrifugation week. In some experiments, the sample incubation was
performed in the presence of 50 mmol/L of either am-at 1000 3 g for 10 minutes, and the cell-free PD effluents
were used. To determine the effect of heat sterilization, inoguanidine (Tokyo Chemical Industry, Tokyo, Japan)
[17] or (6) 2-isopropylidenehydrazono-4-oxo-thiazoli-PD fluids with the same composition as the conventional
heat-sterilized PD fluids (glucose concentrations, 1.36, din-5-ylacetanilide (OPB-9195; a gift from Fujii Memo-
rial Research Institute, Otsuka Pharmaceutical, Ohtsu,2.27, and 3.86%) were prepared and sterilized with a
0.22 mm pore filter. Japan) [16, 18, 19].
Measurements of pentosidineHigh-performance liquid chromatography analysis
High-performance liquid chromatography (HPLC) Plasma ultrafiltrates and PD effluent ultrafiltrates
(50 mL) fortified with BSA were mixed with an equalwas used to identify and quantitate three RCOs for which
pure standards are available, that is, GO, MGO, and volume of 10% trichloroacetic acid and centrifuged at
5000 3 g for five minutes. The supernatant was dis-3-DG. The standards were used for calibration purposes.
Two hundred microliters of 0.025% 2,4-dinitrophenylhy- carded, and the pellet was washed with 300 mL 5% tri-
chloroacetic acid. The pellet was dried by vacuum cen-drazine (DNPH) in 0.5 N HCl were added to 200 mL of
plasma ultrafiltrates or PD effluent ultrafiltrates. After trifugation and acid hydrolyzed in 100 mL of 6 N HCl
for 16 hours at 1108C under nitrogen. The hydrolysatesstanding at 308C for 30 minutes in the dark, 20 mL of 1
mol/L acetone were added to react with excess DNPH were neutralized with 100 mL of 5 N NaOH and 200 mL
of 0.5 mol/L phosphate buffer (pH 7.4), then filteredat 308C for 10 minutes in the dark. The mixture was
washed three times with 200 mL of hexane, and the through a 0.5 mm pore filter, and diluted with phosphate-
buffered saline. The pentosidine content was analyzedremaining aqueous layer was extracted with 200 mL of
octanol. The octanol extract was diluted with acetoni- in duplicate on a reverse-phase HPLC according to our
previous methods [20, 21]. In brief, a 50 mL solutiontrile, and hydrazone derivatives were analyzed by re-
versed-phase HPLC using a Waters Purecil C18 column of diluted acid hydrolysate was injected into an HPLC
system and separated on a Waters purecil C18 column(5 mm, 4.6 3 250 mm) with an absorbance detection at
Miyata et al: Carbonyl stress in PD 427
Fig. 1. Representative high-pressure liquid chromatography (HPLC) chromatograms of peritoneal dialysis (PD) fluids and effluents. (A) Standards
of glyoxal (GO), methylglyoxal (MGO), and 3-deoxyglucosone (3-DG). (B) The filter-sterilized PD fluid. (C) The commercial heat-sterilized PD
fluid, and (D) the PD effluents after a 12-hour dwell time. PD fluids contained a 1.36% glucose. DNPH is the derivatizing agent and RCO-2,4-
dinitrophenylhydrazone is the compound after reaction. Details are in the Methods section. GO, MGO, and 3-DG formed during the heat-
sterilization are major RCOs in the PD fluids (C).
(5 mm, 4.6 3 250 mm). The effluent was monitored using of the carbonyl content obtained in distilled water con-
taining various concentrations of glucose. The level ofa fluorescence detector (RF-10A; Shimadzu, Kyoto, Ja-
pan) and an excitation emission wavelength of 335/385 RCOs other than glucose, hereafter referred to as total
RCOs, was then calculated as the difference betweennm. Synthetic pentosidine was used as a standard [20].
total PD sample carbonyl and glucose-derived carbonyl
Measurement of RCOs level. It should be pointed out that unlike HPLC data,
DNPH results are obtained without standards. They canThe number of RCOs implicated in advanced glyca-
tion and lipoxidation of proteins far exceeds the three be compared only among samples handled with the same
procedures. The several extraction steps probably reducemoieties (GO, MGO, and 3-DG) identified by HPLC.
In the absence of adequate standards, spectrophotome- their concentration to an unknown extent. Thus, the
DNPH results cannot be compared on a molar basis withtry was used to quantitate total RCOs. Two hundred
microliters of 0.025% DNPH in 0.5 N HCl were added the specific RCOs measured by HPLC.
to 200 mL of plasma ultrafiltrates or PD-effluent ultrafil-
Glucose measurementtrates. After standing at 308C for 30 minutes in the dark,
20 mL of 1 mol/L acetone were added to react with excess Glucose was measured by a kit (Glucose CII test;
Wako Pure Chemicals, Osaka, Japan). This assay in-DNPH at 308C for 10 minutes in the dark. The mixture
was washed three times with 200 mL of hexane, and the volves oxidation by glucose oxidase and mutarotation
of glucose by aldose mutarotase. Hydrogen peroxideremaining aqueous layer was extracted with 200 mL of
octanol. The absorbance of the octanol layer was mea- formed is subsequently determined in condensation reac-
tion of 4-aminoantipyrine and phenol catalyzed by horse-sured at 360 nm by a microplate reader (SPECTRA
max 250; Molecular Devices, Sunnyvale, CA, USA). The radish peroxidase [22].
RCO content was calculated as nmol/mL using a stan-
Peritoneal tissue samplesdard curve between DNPH concentration and absorb-
ance [16]. In this method, the glucose-derived carbonyl Peritoneal tissue was obtained through a collaborative
study from 36 nondiabetic patients at the time of a PDgroup also reacts with DNPH. The glucose-derived car-
bonyl content in samples (PD fluids, PD effluents, and catheter insertion or reinsertion. Informed consent was
obtained from each patient. None of the patients hadplasma) were therefore calculated on the basis of the
glucose concentration of samples and a standard curve experienced peritonitis. Patients were divided into three
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Fig. 2. Levels of GO (A), MGO (B), and 3-DG (C) in filter- and heat-
sterilized PD fluids (glucose concentrations: 1.36, 2.27, 3.86%; N 5 3,
each) and in PD effluents (original glucose concentration, 1.36%, N 5
3) after overnight dialysis. The heat-sterilized PD fluids contain a sig-
nificant amount of GO, MGO, and 3-DG. By contrast, their concentra-
tions in the filter-sterilized PD fluids are extremely low. Their concentra-
tions in the PD effluents are significantly lower (P , 0.0001) than in
the heat-sterilized PD fluids. Data are expressed as mean 6 SD.
Table 1. Immunohistochemical detection of protein adducts formed with RCOs in peritoneal tissues of PD patients
Group I (N 5 4) Group II (N 5 16) Group III (N 5 16)
Mesothelial Vascular Mesothelial Vascular Vascular
layer Collagen wall layer Collagen wall Fibrin mantle Collagen wall
CML 2 , 6 2 2 , 6 6 , 1 2 , 1 1 11 1 11
Pentosidine 2 , 6 2 , 6 2 , 6 6 , 1 6 , 1 1 11 1 11
MDA-lysine 2 , 6 2 , 6 2 , 6 6 , 1 6 , 1 1 11 1 11
HNE-adduct 2 , 6 2 , 6 2 , 6 6 , 1 6 , 1 1 11 1 11
Results are expressed as the range of immunostaining intensity observed in each group: (2) negative; (6) weakly positive; (1) moderately positive; (11) strongly
positive. Abbreviations are in the Appendix.
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groups: group I, 4 patients before starting PD (Table 1);
group II, 16 patients on PD for 1.5 to 46 months (average
15.4 months); and group III, 16 patients on PD for 48
to 117 months (average 83.1 months). Patients who had
diabetes were excluded.
Immunohistochemistry
Antipentosidine rabbit IgG [23], anti–4-hydroxyno-
nenal (HNE) rabbit IgG [24], and antimalondialdehyde
(MDA) mouse monoclonal IgG (kindly provided from
Dr. Joseph L. Witztum, University of California San Diego,
San Diego, CA, USA) [25, 26] were used for immunohis-
tochemistry. Anti-AGE mouse monoclonal IgG (6D12)
[27, 28], the major epitope-structure of which was re-
cently identified as Ne -(carboxymethyl)lysine (CML)
[29, 30], was also used.
For indirect immunohistochemical staining, 2 mm thick
sections were mounted on slides coated with 3-amino-
propyltriethoxy silane (Sigma) and were deparaffined,
rehydrated in distilled water, and incubated with Pronase
(0.5 mg/mL; Dako, Glostrup, Denmark) for 15 minutes
at room temperature in a buffer solution containing 0.05
mol/L Tris-HCl, pH 7.2, 0.1 mol/L NaCl. The sections
were washed with phosphate-buffered saline containing
0.05% Tween 20 and blocked in 4% skim milk for two
hours and subsequently incubated with either anti-AGE
mouse monoclonal IgG, antipentosidine rabbit IgG, anti-
MDA mouse monoclonal IgG, or anti-HNE rabbit IgG
overnight in humid chambers at room temperature. The
sections were washed and incubated with 1:100 diluted
goat antirabbit or goat antimouse IgG conjugated with
peroxidase (Dako), respectively, for two hours at room
temperature, followed by the detection with 3,39-diami-
nobenzidine solution containing 0.003% H2O2. Com-
petition experiments to confirm the specificity of im-
munostaining were performed with anti-AGE mouse
monoclonal IgG, antipentosidine rabbit IgG, anti-HNE
mouse monoclonal IgG, or anti-MDA mouse mono-
clonal IgG, which had been preincubated with an excess
of CML-BSA, pentosidine, HNE-BSA, or MDA-BSA,
respectively, for four hours at 378C. Nonimmune rabbit
or mouse IgG was used as a negative control. Immuno-
staining was independently evaluated blindly for inten-
sity and distribution by two observers.
Statistical analysis
Data are expressed as means 6 SD. The unpaired
t-test was used for a statistical evaluation of significant
Fig. 3. Kinetics of clearance of RCOs during PD. The concentrationsdifference between the two groups. of GO (A), MGO (B), and 3-DG (C) are determined in triplicates
in PD effluents (original glucose concentration of PD fluid, 1.36%)
collected from 12-hour dwells of the PD patient. Their concentrations
RESULTS are decreased with increasing dwell time. Data from three PD patients
are expressed as mean 6 SD.RCOs in PD fluids, PD effluents, and plasma
Figure 1 shows representative HPLC chromatograms
of the reference compounds (Fig. 1A) and of the filter-
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Fig. 4. Total RCO contents in PD fluids (N 5
3), PD effluents after a 12-hour dwell time (N 5
14) and in PD plasma (N 5 14). Original glu-
cose level of PD effluents was 1.36%. Samples
were incubated with DNPH, followed by the
determination of RCOs (other than glucose)
content by a spectrophotometric assay. Sam-
ples processed similarly but without DNPH
treatment were used as blanks. Total RCO con-
tent in PD effluent ultrafiltrates is much higher
than those in the filter- and heat-sterilized PD
fluids. It increases with increasing dwell time
and tends to reach levels observed in plasma
ultrafiltrate. Data are expressed as mean 6 SD.
*P , 0.001 compared with filter-sterilized PD
fluids; ‡P , 0.01 compared with heat-sterilized
PD fluids.
sterilized (Fig. 1B) and commercial heat-sterilized (Fig. the level of generated pentosidine was measured. As
shown in Figure 5A, virtually no pentosidine is generated1C) PD fluids: GO, MGO, and 3-DG are the major
identified RCOs in the commercial, heat-sterilized PD in filter-sterilized PD fluids, whereas 42.2 6 5 pmol/mL
pentosidine is formed in heat-sterilized PD fluid. By con-fluid.
The concentrations of GO, MGO, and 3-DG in PD trast, the amount of pentosidine generated in the PD
fluids are represented in Figure 2. Heat-sterilized PD effluents increases linearly with dwell time during the
contains significantly larger amounts of GO (11 to 17 first five hours and more slowly thereafter (Fig. 5B),
mmol/L), MGO (3.5 to 6.2 mmol/L), and 3-DG (42 to 70 reaching values close to those observed after incubation
mmol/L) than filter-sterilized PD fluid (0.6 to 3.0 mmol/L of the plasma sample of the same patient (Fig. 5A).
for GO, approximately 0.07 mmol/L for MGO, and 0.6 Pentosidine yields in PD effluents after a 12-hour dwell
to 2.0 mmol/L for 3-DG). The concentration of GO, are significantly higher than those in fresh heat-sterilized
MGO, and 3-DG increases in parallel with PD fluid PD fluids (P , 0.05).
glucose content. As shown in Figures 1D and 2, the The addition of aminoguanidine or OPB-9195 to the
PD effluents, collected after a 12-hour dwell, contain incubation medium prevents the generation of pentosi-
significantly lower levels of GO, MGO, and 3-DG than dine (Fig. 5A). Both compounds are inhibitors of the
the heat-sterilized PD fluids. The kinetics of this fall have carbonyl-amine chemistry leading to AGE formation
been evaluated in three patients and are represented in [16, 17, 19]. These observations confirm that the AGE
Figure 3. The decrease is evident within one to two hours precursors accumulating in the PD effluents are indeed
and proceeds more slowly thereafter. Glucose concentra- RCOs.
tions in PD effluents decline in parallel (data not shown).
Immunohistochemical detection of protein adductsLevels of total RCOs, precursors of AGEs, were mea-
formed by RCOs in peritoneal tissuessured in PD fluids and effluents by the DNPH method.
As shown in Figure 4, total RCO levels are very low in Peritoneal samples were stained with antibodies spe-
cific for various advanced glycation (CML and pentosi-filter-sterilized PD fluids, but are significantly higher in
commercial heat-sterilized PD fluids. In contrast with dine) or lipoxidation (MDA-lysine and HNE-protein
adduct) end products. The former are formed from car-GO, MGO, and 3-DG levels, total RCO levels increase
in PD effluents collected after a 12-hour dwell. bohydrate-derived RCOs and the latter from lipid (un-
saturated fatty acids such as arachidonate)-derivedTo confirm the biological significance for AGE gener-
ation of the elevated levels of total RCOs observed in RCOs. The results are summarized in Table 1.
In samples obtained from patients prior to PD (groupthe PD effluents, cell-free ultrafiltrated PD fluid samples
fortified with BSA were incubated for one week, and I), immunostaining is faint (CML staining; Fig. 6A). The
Fig. 5. Generation of pentosidine in PD fluids,
PD effluents, and in PD plasma (N 5 3, each;
A) and the kinetics of pentosidine generation
during dialysis (B). The contents of pentosidine
generated upon incubation of PD fluids, PD
effluent (after a 12-hour dwell) ultrafiltrates,
and PD plasma ultrafiltrates, fortified with BSA
were determined by HPLC assay. The PD fluid
glucose concentration is 1.36%. In some experi-
ments, incubations were performed in the pres-
ence of aminoguanidine or OPB-9195 (final
concentrations, 50 mmol/L). The amount of
pentosidine generated during incubation of PD
effluent (after a 12-hour dwell) ultrafiltrates is
significantly higher than that of the filter- and
heat-sterilized PD fluids: It increases with in-
creasing dwell time and tends to reach levels
observed after incubation of plasma ultrafil-
trate. Data are expressed as means 6 SD. *P ,
0.001 compared with filter-sterilized PD fluids;
‡P , 0.005 compared with heat-sterilized PD
fluids; **P , 0.01 compared with filter-steri-
lized PD fluids; §P , 0.05 compared with heat-
sterilized PD fluids; NS, not significant.
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Fig. 6. Immunohistochemical detection of AGEs and ALEs in peritoneal tissues from PD patients. Peritoneal tissue sections from a 65-year-old
patient on hemodialysis (group I in Table 1; A) and from a 52-year-old patient on PD for 117 months (group III; B–F) were stained with hematoxylin
and eosin (B) or immunostained for CML (A and C), pentosidine (D), MDA-lysine (E), and HNE-protein adduct (F). Nuclei were counterstained
with Meyer’s hematoxylin. The staining for AGEs and ALEs was faint in hemodialysis patients not undergoing PD (A). AGE and ALE stainings
were strongly positive in the mesothelial layers and vascular walls of the peritoneal tissue of patients on long-term PD (C–F). Note that the
distributions of AGEs and ALEs were identical. A–F 3200.
picture is different in samples obtained from patients on from weak or absent to moderate. Vascular immuno-
staining is consistently moderate. After more than fivePD. After less than five years of PD (group II), mesothe-
lial layers and connective tissue immunostaining are years of PD (group III), the peritoneal membrane ap-
pears modified by interstitial fibrosis, the disappearanceidentical for the four adducts in each patient, ranging
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Fig. 6. (Continued).
of mesothelial cells, fibrin deposition on membrane sur- ability to form AGEs on the peritoneal membrane in
faces, and thickening with hyalinosis of the vascular wall vivo appears more limited. First, their level decreases as
(Fig. 6B). Immunostaining intensity is similar for CML dwell time increases, likely as a consequence of diffusion
(Fig. 6C), pentosidine (Fig. 6D), MDA-lysine (Fig. 6E), across the peritoneal membrane into the bloodstream.
and HNE-protein adduct (Fig. 6F). It is more severe Second and more important, they generate only small
than that in group II patients. It is consistently strong in amounts of pentosidine, an AGE compound, during a one-
the fibrin mantle of the mesothelial layers and in the week incubation of fresh PD fluids fortified with BSA.
vascular walls and is moderate in interstitial collagen Examination of the changes in RCOs during dwell
(Table 1). The immunostaining is specific, as demon- time reveals a reverse pattern. Whereas GO, MGO, 3-DG,
strated by its complete inhibition in the presence of an as well as of glucose levels originally present in the PD
excess of competitors (data not shown). No immunoreac- fluid decrease, total RCO levels measured by DNPH
tion is visible in the presence of nonimmune mouse or increase progressively to eventually reach concentrations
rabbit IgG. similar to those observed in plasma. This process likely
corresponds to the diffusion of circulating serum RCOs
into the peritoneal cavity.DISCUSSION
The progressive rise of RCOs plays a significant roleThe high glucose content of PD fluids has been incrimi-
in AGE genesis. Indeed, a one-week incubation of PDnated in the genesis of advanced glycation of the perito-
effluent fortified with BSA leads to the formation of sig-neal membrane proteins [2, 3, 5]. Efforts to replace glu-
nificant amounts of pentosidine used as a surrogate markercose by other osmotic agents have thus been undertaken.
for AGEs. Pentosidine generation increases with dwellThe present study casts a new light on this phenomenon.
time and eventually reaches the level observed after aIt demonstrates that AGE formation in the peritoneal
similar incubation of the corresponding uremic serum.cavity relies not only on the presence of glucose-derived
The observation that pentosidine generation duringRCOs in the PD fluids, but also on the diffusion of RCOs
incubation is inhibited by the addition of aminoguani-from systemic circulation.
dine or OPB-9195 further demonstrates that RCOs areThe RCO content of commercial PD fluids, measured
the precursors of pentosidine. Indeed, both compoundseither by the DNPH reaction or by HPLC, is initially
inhibit the carbonyl-amino reaction, which determinesvery low but rises after heat sterilization. The major
the formation of AGEs, including pentosidine.RCOs present in the PD fluids include GO, MGO, and
3-DG, all of which are able to form AGEs in vitro. Their We have recently demonstrated that the RCOs accu-
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mulating in uremic plasma are derived not only from to call “carbonyl stress” the accumulation in the serum
carbohydrates but also from lipids, such as polyunsatu- of RCOs and their attendant modification of proteins
rated fatty acids [14–16]. If, as may be anticipated from by AGEs and ALEs [14]. By analogy, we suggest that
their small size, these various RCOs diffuse within the the peritoneal cavity also mirrors a state of carbonyl
peritoneal cavity, it may be expected that the protein stress.
adducts formed in the peritoneum will include not only In conclusion, we demonstrate a predominant role of
AGEs, such as pentosidine, which originates from carbo- circulating RCOs in uremia in the genesis of various
hydrate-derived RCOs, but also ALEs, such as MDA- AGEs and ALEs within the peritoneal membrane.
lysine, which originate from lipid-derived RCOs. This RCOs might alter the quality of the peritoneal mem-
hypothesis has been verified by the immunohistochemi- brane, not only through the formation of AGEs and
cal study of peritoneal samples. As previously described ALEs, but also through a direct effect on cell functions.
by other authors [3], we confirm the presence of two The strategies designed to decrease RCOs or their effects
AGE compounds, pentosidine and CML. More impor- on AGE and ALE formation should prove at least as
tant, we demonstrate an identical distribution of ALEs, rewarding to preserve the peritoneal membrane as ef-
MDA-lysine, and HNE-protein adduct in the mesothe- forts to reduce the glucose content in PD fluids.
lial layer and vascular walls. As the latter adducts cannot
proceed from glucose degradation products present in ACKNOWLEDGMENTS
commercial heat-sterilized PD fluids, their colocalization
This study was supported by grants from Research for the Futurewith AGEs confirm the important role played by circu- Program of the Japan Society for the Promotion of Science (96 l00303),
lating RCOs crossing the peritoneal membrane during from the Japanese Ministry of Health and Welfare for Research on
Health Services (H10-079), and from the Baxter Healthcare Corpora-PD. The trustworthiness of these results relies on the
tion. We thank Drs. Satoshi Sugiyama, Ryouji Tanabe, and Makotohigh specificity of the utilized antibodies, demonstrated
Nishina for providing plasma and PD effluents of PD patients.
by minimal cross-reactivity assessed by competition with
Reprint requests to Toshio Miyata, M.D., Ph.D., Molecular and Cel-albumin modified with related epitopes [23, 31].
lular Nephrology, Institute of Medical Sciences and Department of Inter-Our observations also provide a frame of reference
nal Medicine, Tokai University School of Medicine, Bohseidai, Isehara,
for AGE and ALE modification of peritoneal proteins Kanagawa 259-1193, Japan.
as a function of dialysis duration. Negative or faint immu-
nostaining does not appear specific for the peritoneum
APPENDIXexposed to PD fluid, as it is already present prior to PD.
The first deposits appear in the walls of peritoneal vessels Abbreviations used in this article are: AGEs, advanced glycation
end products; ALEs, advanced lipoxidation end products; BSA, bovinewithin 1 to 46 months. Over the subsequent year (48 to
serum albumin; CML, Ne-(carboxymethyl)lysine; 3-DG, 3-deoxygluco-117 months), immunostaining increases in the vascular
sone; DNPH, 2,4-dinitrophenylhydrazine; GO, glyoxal; HNE, 4-hydroxy-
walls and extends to the interstitial collagen and to the nonenal; HPLC, high-performance liquid chromatography; MDA,
malondialdehyde; MGO, methylglyoxal; PD, continuous ambulatoryfibrin deposited at the mesothelial surface.
peritoneal dialysis; RCO, reactive carbonyl compound.Immunostaining for AGEs [3] and ALEs in the perito-
neum is only faintly positive or negative in tissues of
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